Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	ORR	Up to approximately 24 months	Objective Response Rate
Primary	Optimal combination dose (only IIa)	Up to approximately 24 months	Optimal combination dose of SI-B001 with chemotherapy (only IIa)
Secondary	OS	Up to approximately 24 months	Overall Survival
Secondary	PFS	Up to approximately 24 months	Progression Free Survival
Secondary	DCR	Up to approximately 24 months	Disease Control Rate
Secondary	DOR	Up to approximately 24 months	Duration of Response
Secondary	TEAE	Up to approximately 24 months	Treatment Emergent Adverse Events
Secondary	Cmax	Up to approximately 24 months	Maximum serum concentration
Secondary	Tmax	Up to approximately 24 months	Time to maximum serum concentration
Secondary	Ctrough	Up to approximately 24 months	Minimum serum concentration
Secondary	ADA	Up to approximately 24 months	anti-SI-B001 antibody

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05020457/registered